Cyclohexanecarboxamide, 4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]- manufacturers
- MCC
-
- $87.00
-
2026-07-15
- CAS:104676-09-7
- Purity:
- Supply Ability: 10g
- MCC
-
-
2025-06-07
- CAS:104676-09-7
- Min. Order: 50mg
- Purity: >95.00%
- Supply Ability: 50mg
|
| | Cyclohexanecarboxamide, 4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]- Basic information |
| | Cyclohexanecarboxamide, 4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]- Chemical Properties |
| Boiling point | 468.5±14.0 °C(Predicted) | | density | 1.280±0.06 g/cm3(Predicted) | | form | Solid | | pka | 16.71±0.40(Predicted) | | color | Light yellow to brown |
| | Cyclohexanecarboxamide, 4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]- Usage And Synthesis |
| Uses | MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1[1]. | | Biological Activity | MCC is non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs), such as MCC-DM1[1].
Antibody-drug conjugates (ADCs) are potent cytotoxic drugs linked to antibodies through chemical linkers, and allow specific targeting of drugs to neoplastic cells. Anti-CD22-MCC-DM1 is broadly effective in vitro against multiple NHL cell lines[1]. | | References | [1]. Polson AG, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia. 2010;24(9):1566-1573. |
| | Cyclohexanecarboxamide, 4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]- Preparation Products And Raw materials |
|